Anxiety Disorders
DFTXDefinium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.)Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for DT120 (formerly MM120; lysergide D-tartrate) in Anxiety Disorders. The expected timing is based on the latest available company guidance and may change.
Voyage and Panorama studies. 12/16/24- 1st patient dosed (Voyage study). 1/30/25- 1st patient dosed (Panorama study). 5/8/25- 12wk topline data in H1 2026 (Voyage) and H2 2025 (Panorama). 11/06/25:- Voyage Ph3 GAD topline expected H1 2026. Panorama Ph3 topline now expected H2 2026. JAMA Ph2b published. 05/07/26:- Voyage enrollment completed; topline early Q3 2026. Panorama enrollment complete; topline late Q3 2026 (timeline updated). 08/06/26:- Voyage and Panorama enrolled; data expected week of August 10 and September 2026. 08/12/26:- Voyage Phase 3 topline positive. Panorama Phase 3 topline expected in September 2026.
Verification
Confirm timing and program details against the company announcement or filing.